Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
A Multi-center, Active-controlled (5 mg daily risedronate), Double-blind, Randomized, Sequential Escalating Dose Study to Assess Safety, Pharmacokinetics and Efficacy of 100, 150, and 200 mg Oral Risedronate Administered Monthly for Six Months in Postmenopausal Women with Low Bone Mineral Density.
Epistemonikos ID: 26be6515702bd0ebca76cbdb773de253cfdd8611
First added on: May 04, 2024